Legumain protein as a potential predictive biomarker for Asian patients with breast carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 24, 2014, Pages 10773-10777

  Wu, Mei ^a   Shao, Guang Rui ^a   Zhang, Fei Xue ^a   Wu, Wen Xiu ^a   Xu, Ping ^a   Ruan, Zheng Min ^a  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Breast cancer; Legumain; Positive expression; Prognostic biomarker

Indexed keywords

CYSTEINE PROTEINASE; ESTROGEN RECEPTOR; LEGUMAIN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ASIA; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; ENZYMOLOGY; FEMALE; FOLLOW UP; HUMAN; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION;

ADULT; AGED; ASIA; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CYSTEINE ENDOPEPTIDASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84923052582     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.24.10773     Document Type: Article

References (21)

1. Asiaf A, Ahmad ST, Aziz SA, et al (2014). Loss of expression and abberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir. Asian Pac J Cancer Prev, 15, 6397-403.
2. Casas A, Llombart A, Martin M (2013). Denosumab for the treatment of bone metastases in advanced breast cancer. Breast, 22, 585-92.
3. Chen JM, Fortunato M, Stevens RA, et al (2001). Activation of progelatinase A by mammalian legumain, a recently discovered cysteine proteinase. Biol Chem, 382, 77-83.
4. Elzawawy A (2008). Breast cancer systemic therapy: the need for more economically sustainable scientific strategies in the world. Breast Care, 3, 434-8.
5. Gawenda J, Traub F, Luck HJ, et al (2007). Legumain expression as a prognostic factor in breast cancer patients. Breast Cancer Res Treat, 102, 1-6.
6. Guo P, Zhu A, Sun Z, et al (2013). Expression of legumain correlates with prognosis and metastasis in gastric carcinoma. PLoS One, 8, 73090.
7. Hu Q, Luo Z, Xu T, et al (2014). FOXA1: a promising prognostic marker in breast cancer. Asian Pac J Cancer Prev, 15, 11-6.
8. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
9. Lewen A, Zhou H, Hu HD, et al (2008). A legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother, 57, 507-15.
10. Liu C, Sun X, Huang H, et al (2003). Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy. Cancer Res, 63, 2957-64.
11. Luo Y, Zhou H, Krueger J, et al (2006). Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest, 116, 2132-41.
12. Murthy RV, Arbman G, Gao J, et al (2005). Legumain expression in relation to clinicopathologic and biological variables in colorectal cancer. Clin Cancer Res, 11, 2293-9.
13. Parajuly SS, Lan PY, Yu MB, et al (2012). Diagnostic potential of strain ratio measurement and a 5 point scoring method for detection of breast cancer: Chinese experience. Asian Pac J Cancer Prev, 13, 1447-52.
14. Reisfeld RA (2013). The tumor microenvironment: a target for combination therapy of breast cancer. Crit Rev Oncog, 18, 115-33.
15. Rustogi A, Budrukkar A, Dinshaw K, et al (2005). Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther, 1, 21-30.
16. Santamaria ME, Hernandez-Crespo P, Ortego F, et al (2012). Cysteine peptidases and their inhibitors in Tetranychus urticae: a comparative genomic approach. BMC Genomics, 13, 307.
17. Sevenich L, Schurigt U, Sachse K, et al (2010). Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc Natl Acad Sci USA, 107, 2497-502.
18. Taib NA, Akmal M, Mohamed I, Yip CH. (2011). Improvement in survival of breast cancer patients-trends over time periods in a single institution in an Asian Pacific country, Malaysia. Asian Pac J Cancer Prev, 12, 345-9.
19. Velaiutham S, Taib NA, Ng KL, Yoong BK, Yip CH (2008). Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer. Asian Pac J Cancer Prev, 9, 445-8.
20. Wang L, Chen S, Zhang M, et al (2012). Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer. J Cell Biochem, 113, 2679-86.
21. Wu W, Luo Y, Sun C, et al (2006). Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res, 66, 970-80.